Investment
Features
FeesSafety
Academy
More
Pluang+

Compare DexCom, Inc. (DXCM) vs SOLAI Limited (SLAI) Price & Performance

DexCom, Inc.Trade
SOLAI LimitedTrade

Price performance (Past 24H)

Key statistics

DexCom, Inc. vs SOLAI Limited — how do they compare? DexCom, Inc. trades at $90.64 (market cap $33.79B), while SOLAI Limited trades at $3.72 (market cap $16.69M). The key difference: DexCom, Inc. is far larger — about 2024.6× SOLAI Limited's market cap, and DexCom, Inc. is trading nearer its 52-week high, SOLAI Limited nearer its low. Which is the better fit depends on your goals.

DXCMSLAI
Market Cap
$33.79B$16.69M
Sector
HealthTechnology
52-Week High
$89.53$26.74
52-Week Low
$54.84$2.74
Enterprise Value
$33.24B$16.33M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

DexCom, Inc.

DXCM trades at $91.00, up 3.82% today and near its 52-week high, with bullish technical signals from moving averages and strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $0.70 versus $0.61 expected, driven by 13% revenue growth and margin expansion. The company raised full-year 2026 guidance, reflecting robust demand for continuous glucose monitors.

The outlook is positive due to sustained revenue growth, profitability improvements, and analyst consensus favoring buys. Risks include competitive pressures and potential regulatory scrutiny, but institutional ownership trends and earnings momentum support a constructive view for investors seeking exposure to medical technology.

SOLAI Limited

SLAI trades at $3.72 with no recent price movement, showing mixed technical signals despite a bullish overall rating. The company faces severe financial distress with negative profit margins (-134.63% net income margin) and declining revenue, compounded by NYSE delisting proceedings initiated in July 2026. Recent corporate actions include a 7:1 reverse stock split completed in July 2026 and the acquisition of a 51% stake in NEURALAND, signaling strategic shifts amid operational challenges.

The outlook remains highly speculative with significant execution and liquidity risks. While technical indicators suggest potential short-term momentum, fundamental weaknesses and delisting uncertainty create substantial downside risk. Investors should approach with caution given the company's negative profitability and regulatory challenges.

Returns comparison

Trailing returns across standard periods

About DexCom, Inc.

Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.

Read more on DXCM

About SOLAI Limited

SOLAI focuses on providing innovative AI-driven software solutions. The company leverages artificial intelligence to enhance digital experiences and optimize business processes for various industries.

Read more on SLAI